Literature DB >> 13737086

Chloroquine diphosphate in rheumatoid arthritis. A controlled trial.

A J POPERT, K A MEIJERS, J SHARP, F BIER.   

Abstract

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID/therapy; CHLOROQUINE/therapy

Mesh：

Substances：

Year:  1961        PMID： 13737086      PMCID： PMC1007179          DOI： 10.1136/ard.20.1.18

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

1.  Medical and social aspects of the treatment of rheumatoid arthritis; with special reference to factors affecting prognosis.

Authors:  J J DUTHIE; M THOMPSON; M M WEIR; W B FLETCHER
Journal:  Ann Rheum Dis       Date:  1955-06       Impact factor: 19.103

2.  Clinical significance of the rheumatoid serum factor.

Authors:  J H KELLGREN; J BALL
Journal:  Br Med J       Date:  1959-02-28

3.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

4.  Corneal complication of chloroquine (aralen) phosphate therapy.

Authors:  R W ZELLER; D DEERING
Journal:  J Am Med Assoc       Date:  1958-12-27

5.  Two-year comparative study of serial hemagglutination tests done on groups of rheumatoid arthritis patients.

Authors:  G K DE FOREST; M B MUCCI; P L BOISVERT
Journal:  Arthritis Rheum       Date:  1958-10

6.  Retinopathy following chloroquine therapy.

Authors:  H E HOBBS; A SORSBY; A FREEDMAN
Journal:  Lancet       Date:  1959-10-03       Impact factor: 79.321

7.  A controlled study of chloroquine as an antirheumatic agent.

Authors:  A S COHEN; E CALKINS
Journal:  Arthritis Rheum       Date:  1958-08

8.  Chloroquine and rheumatoid arthritis; a short-term controlled trial.

Authors:  A FREEDMAN
Journal:  Ann Rheum Dis       Date:  1956-09       Impact factor: 19.103

9.  "BLUE HALOES" IN ATEBRIN WORKERS.

Authors:  I Mann
Journal:  Br J Ophthalmol       Date:  1947-01       Impact factor: 4.638

10.  Unusual toxic manifestations to amodiaquin (camoquin).

Authors:  D C BLEIL
Journal:  AMA Arch Derm       Date:  1958-01
View more
  22 in total

1.  Effect of certain anti-arthritic compounds on the permeability of synovial membrane in the rabbit.

Authors:  G W SHARP
Journal:  Ann Rheum Dis       Date:  1963-01       Impact factor: 19.103

2.  Axon reflex sweating in rheumatoid arthritis.

Authors:  J L KALLIOMAKI; H A SAARIMAA; P TOIVANEN
Journal:  Ann Rheum Dis       Date:  1963-01       Impact factor: 19.103

3.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

4.  Controversies in the treatment of rheumatoid arthritis.

Authors:  O Savage
Journal:  Proc R Soc Med       Date:  1969-02

5.  Effect of auranofin on plasma fibronectin, C reactive protein, and albumin levels in arthritic rats.

Authors:  K M Connolly; V J Stecher; D J Pruden
Journal:  Ann Rheum Dis       Date:  1988-06       Impact factor: 19.103

6.  Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study.

Authors:  P D Fowler; M F Shadforth; P R Crook; A Lawton
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

7.  Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis.

Authors:  S P Percival; I Meanock
Journal:  Br Med J       Date:  1968-09-07

8.  Chloroquine in long-term treatment of rheumatoid arthritis.

Authors:  A Bjelle; A Björnham; A Larsen; T Mjörndal
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

9.  Chloroquine retinopathy: is there a safe daily dose?

Authors:  J S Marks
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

10.  Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

Authors:  R B Landewé; A M Miltenburg; M J Verdonk; C L Verweij; F C Breedveld; M R Daha; B A Dijkmans
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.